These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

715 related articles for article (PubMed ID: 26751506)

  • 21. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. GLP-1 receptor agonists for Parkinson's disease.
    Mulvaney CA; Duarte GS; Handley J; Evans DJ; Menon S; Wyse R; Emsley HC
    Cochrane Database Syst Rev; 2020 Jul; 7(7):CD012990. PubMed ID: 32700772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience.
    Parashos SA; Swearingen CJ; Biglan KM; Bodis-Wollner I; Liang GS; Ross GW; Tilley BC; Shulman LM;
    Arch Neurol; 2009 Sep; 66(9):1099-104. PubMed ID: 19597081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trial of Lixisenatide in Early Parkinson's Disease.
    Meissner WG; Remy P; Giordana C; Maltête D; Derkinderen P; Houéto JL; Anheim M; Benatru I; Boraud T; Brefel-Courbon C; Carrière N; Catala H; Colin O; Corvol JC; Damier P; Dellapina E; Devos D; Drapier S; Fabbri M; Ferrier V; Foubert-Samier A; Frismand-Kryloff S; Georget A; Germain C; Grimaldi S; Hardy C; Hopes L; Krystkowiak P; Laurens B; Lefaucheur R; Mariani LL; Marques A; Marse C; Ory-Magne F; Rigalleau V; Salhi H; Saubion A; Stott SRW; Thalamas C; Thiriez C; Tir M; Wyse RK; Benard A; Rascol O;
    N Engl J Med; 2024 Apr; 390(13):1176-1185. PubMed ID: 38598572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort.
    Chou KL; Elm JJ; Wielinski CL; Simon DK; Aminoff MJ; Christine CW; Liang GS; Hauser RA; Sudarsky L; Umeh CC; Voss T; Juncos J; Fang JY; Boyd JT; Bodis-Wollner I; Mari Z; Morgan JC; Wills AM; Lee SL; Parashos SA;
    J Neurol Sci; 2017 Jun; 377():137-143. PubMed ID: 28477684
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical evolution of Parkinson's disease and prognostic factors affecting motor progression: 9-year follow-up study.
    Reinoso G; Allen JC; Au WL; Seah SH; Tay KY; Tan LC
    Eur J Neurol; 2015 Mar; 22(3):457-63. PubMed ID: 24888502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pingchan granule for depressive symptoms in parkinson's disease: A randomized, double-blind, placebo-controlled trial.
    Gu SC; Zhou J; Ye Q; Yuan CX
    J Integr Med; 2021 Mar; 19(2):120-128. PubMed ID: 33446472
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence, determinants, and effect on quality of life of freezing of gait in Parkinson disease.
    Perez-Lloret S; Negre-Pages L; Damier P; Delval A; Derkinderen P; Destée A; Meissner WG; Schelosky L; Tison F; Rascol O
    JAMA Neurol; 2014 Jul; 71(7):884-90. PubMed ID: 24839938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.
    Beavan M; McNeill A; Proukakis C; Hughes DA; Mehta A; Schapira AH
    JAMA Neurol; 2015 Feb; 72(2):201-8. PubMed ID: 25506732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of Low Body Mass Index in Patients with Parkinson's Disease: A Multicenter Case-Control Study.
    Suzuki K; Okuma Y; Uchiyama T; Miyamoto M; Haruyama Y; Kobashi G; Sakakibara R; Shimo Y; Hatano T; Hattori N; Yamamoto T; Hirano S; Yamamoto T; Kuwabara S; Kaji Y; Fujita H; Kadowaki T; Hirata K
    J Parkinsons Dis; 2020; 10(1):213-221. PubMed ID: 31868678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caffeine as symptomatic treatment for Parkinson disease (Café-PD): A randomized trial.
    Postuma RB; Anang J; Pelletier A; Joseph L; Moscovich M; Grimes D; Furtado S; Munhoz RP; Appel-Cresswell S; Moro A; Borys A; Hobson D; Lang AE
    Neurology; 2017 Oct; 89(17):1795-1803. PubMed ID: 28954882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
    Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
    J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trial of Deferiprone in Parkinson's Disease.
    Devos D; Labreuche J; Rascol O; Corvol JC; Duhamel A; Guyon Delannoy P; Poewe W; Compta Y; Pavese N; Růžička E; Dušek P; Post B; Bloem BR; Berg D; Maetzler W; Otto M; Habert MO; Lehericy S; Ferreira J; Dodel R; Tranchant C; Eusebio A; Thobois S; Marques AR; Meissner WG; Ory-Magne F; Walter U; de Bie RMA; Gago M; Vilas D; Kulisevsky J; Januario C; Coelho MVS; Behnke S; Worth P; Seppi K; Ouk T; Potey C; Leclercq C; Viard R; Kuchcinski G; Lopes R; Pruvo JP; Pigny P; Garçon G; Simonin O; Carpentier J; Rolland AS; Nyholm D; Scherfler C; Mangin JF; Chupin M; Bordet R; Dexter DT; Fradette C; Spino M; Tricta F; Ayton S; Bush AI; Devedjian JC; Duce JA; Cabantchik I; Defebvre L; Deplanque D; Moreau C;
    N Engl J Med; 2022 Dec; 387(22):2045-2055. PubMed ID: 36449420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rotigotine in Combination with the MAO-B Inhibitor Selegiline in Early Parkinson's Disease: A Post Hoc Analysis.
    Giladi N; Asgharnejad M; Bauer L; Grieger F; Boroojerdi B
    J Parkinsons Dis; 2016 Apr; 6(2):401-11. PubMed ID: 27061066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The relationships between the unified Parkinson's disease rating scale and lower extremity functional performance in persons with early-stage Parkinson's disease.
    Song J; Fisher BE; Petzinger G; Wu A; Gordon J; Salem GJ
    Neurorehabil Neural Repair; 2009 Sep; 23(7):657-61. PubMed ID: 19336530
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contribution of aging to the severity of different motor signs in Parkinson disease.
    Levy G; Louis ED; Cote L; Perez M; Mejia-Santana H; Andrews H; Harris J; Waters C; Ford B; Frucht S; Fahn S; Marder K
    Arch Neurol; 2005 Mar; 62(3):467-72. PubMed ID: 15767513
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Functional Decline in Early Parkinson's Disease: NET-PD LS1 Cohort.
    Bega D; Kim S; Zhang Y; Elm J; Schneider J; Hauser R; Fraser A; Simuni T
    J Parkinsons Dis; 2015; 5(4):773-82. PubMed ID: 26639661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pingchan Granule for Motor Symptoms and Non-Motor Symptoms of Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled Study.
    Gu SC; Ye Q; Wang CD; Zhao SR; Zhou J; Gao C; Zhang Y; Liu ZG; Yuan CX
    Front Pharmacol; 2022; 13():739194. PubMed ID: 35281890
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.